Entera Bio Ltd. (ENTX) is a publicly-traded biotechnology company whose primary focus is the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company was established in 2010 and has its headquarters in Jerusalem, Israel.
ENTX has harnessed its proprietary technology to develop an innovative platform for oral delivery of large molecules, such as proteins, peptides, and antibodies, that are typically injected. This revolutionary approach has the potential to drastically improve patient treatment by eliminating the need for frequent injections, thus leading to enhanced patient compliance, and potentially, better treatment outcomes.
Entera Bio Ltd.'s product pipeline includes a number of innovative therapies, most notably the oral parathyroid hormone (1-34), or PTH, for osteoporosis and hypoparathyroidism. This treatment is intended to maintain and enhance bone health, thus significantly improving quality of life for patients suffering from these debilitating conditions. Other products under development cover a range of conditions including inflammatory bowel disease, diabetes, and hemophilia.
ENTX prides itself on its commitment to innovation, safety, and efficacy. Numerous preclinical and clinical trials have demonstrated the potential of its oral delivery technology, and the company is continuously working on refining and expanding its product portfolio.
In addition to its internal research and development efforts, Entera Bio Ltd. has established partnerships with leading pharmaceutical companies and research institutions to advance its technology and develop novel therapeutics.
Financially, ENTX is listed on the NASDAQ, under the ticker symbol "ENTX", thereby offering opportunities for investors to participate in the company's progress. Notably, in recent years, the company has made significant strides towards commercialization of its products which may revolutionize the way large molecule biologic treatments are administered.
As a player in the competitive biotechnology industry, Entera Bio Ltd.'s success hinges on its continued innovation, robust product pipeline, and commitment to improving the lives of patients. The company's groundbreaking technology positions it at the forefront of oral drug delivery advancement in the biotech space, with considerable potential for growth and development in the coming years.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Entera Bio Ltd. (NASDAQ: ENTX) has successfully raised $275 million through an oversubscribed private placement, primarily to fund Phase 3 trials for its osteoporosis drug candidate, EB613. This capital injection is expected to extend the company's cash runway into 2030 and was led by existing investor BVF Partners. Despite potential dilution, the news led to a rebound in share prices, reflecting strong institutional confidence in EB613's commercial potential.
Entera Bio (NASDAQ:ENTX) saw its stock price increase by 5.1% to $3.27, although trading volume was significantly lower than average. Analyst sentiment is mixed, with a consensus "Hold" rating and a target price of $9.00. The company reported a quarterly loss of $0.14 per share, missing the consensus estimate, and institutional investors collectively own 14.11% of the stock.
Renaissance Technologies LLC significantly increased its stake in Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% in the first quarter, acquiring 365,441 additional shares to hold a total of 473,442 shares. This boosted their ownership to approximately 0.96% of the company. Other institutional investors also adjusted their holdings, while analyst sentiment remains mixed with a "Hold" rating and a $9.00 price target.